Our present study showed a significant correlation between FAK-copy-gain and sensitivity to its targeted drug, F14, in breast cancer, suggesting that FAK-copy-gain can be an effective predictive molecular marker in the selection of candidate patients for treatment with FAK inhibitors. This evidence concerns the gene PTK2 and breast carcinoma.